- May 12, 2026 Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
- May 07, 2026 Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
- Apr 21, 2026 Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
- Apr 09, 2026 Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
- Mar 11, 2026 Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
- Feb 24, 2026 Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
- Feb 23, 2026 Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
- Feb 03, 2026 Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
- Jan 13, 2026 Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
- Jan 09, 2026 Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Displaying 1 - 10 of 119